Qilu Pharmaceutical Initiates New Phase III Clinical Trial of 'Aito Combination Antibody' (QL1706) in Advanced Ovarian Clear Cell Carcinoma

On June 3, a project was registered on the ClinicalTrials website aimed atA Phase III Clinical Study to Evaluate the Efficacy of QL1706 Combined with Bevacizumab as First-Line Treatment for Advanced Ovarian Clear Cell Carcinoma（NCT07002346）。

This is a randomized, open-label, parallel-assigned Phase III clinical trial, planning to enroll 226 subjects, who will be randomly assigned to receiveQL1706 in combination with bevacizumab, paclitaxel, and carboplatin chemotherapy. The specific dosing regimen is as follows.

Source: ClinicalTrials Official Website

The primary endpoint isBICR assessed according to RECIST v1.1Progression-Free Survival(PFS), secondary endpoints include investigator-assessed PFS, overall survival (OS), etc. The study is planned to start on June 1, 2025, and be completed on June 1, 2029.

QL1706 (Aipalorituo Weirui Monoclonal Antibody, also known as Aituo Combination Antibody) isQilu Pharmaceutical Utilizes MabPair^®The world's first dual-function combination antibody developed on a biotechnology platform, consisting of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4. Previously, Qilu Pharmaceutical initiated clinical research on the combination of this product with bevacizumab for hepatocellular carcinoma and gastric cancer.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb